J. Dillberger, LLC 4121 Lower Schooner Road |
|
J. Dillberger, LLC is a consulting firm specializing in the creation and execution of nonclinical safety plans that produce successful regulatory applications for drugs, biologics, medical devices, and combination products. The company’s aim is to help clients rapidly, efficiently, and cost-effectively discover and develop new therapies, initiate clinical trials, and gain marketing approval. In addition to these activities, the company also:
The company’s core services are directed to the creation and execution of nonclinical safety evaluation programs and the successful integration and presentation of safety information to speed the discovery and development of new therapies. Specific services include:
John E. Dillberger, DVM, PhD
Diplomate ACVP and ABT, Fellow IATP
President and Founder
Over his 18-year career, Dr. Dillberger has held positions of increasing responsibility at Marion Merrell Dow, GlaxoWellcome, and Triangle Pharmaceuticals. He has served as Head of US Pathology, Director of Safety Evaluation for US-Based Development Projects, and Worldwide Specialist in Oncology Drug Projects for GlaxoWellcome and as Director of Toxicology at Triangle Pharmaceuticals. Dr. Dillberger has prepared safety evaluation packages for numerous preIND and preIDE meetings, IND and IDE applications, and clinical trial and marketing applications in the USA and Europe, including the recent NDA for Coviracil® and CTD for ThelinÔ. Dr. Dillberger has been certified in Veterinary Pathology by the American College of Veterinary Pathologists since 1987 and in Toxicology by the American Board of Toxicology since 1992. In 2001, he was one of the first fellows accepted into the International Academy of Toxicologic Pathology.